STOCKS TELEGRAPH

Tag: BTAI Stock

  • BioXcel (BTAI) Stock Climbs As FDA Clears Clinical Trial Site Inspection

    BioXcel (BTAI) Stock Climbs As FDA Clears Clinical Trial Site Inspection

    Following a significant regulatory update, BioXcel Therapeutics, Inc. (NASDAQ: BTAI) stock saw a sharp increase in value. As of the recent market check, BTAI stock price rose by 96.14%, reaching $4.20. This significant rise is a reaction to recent events involving the FDA’s (U.S. Food and Drug Administration) assessment of its clinical trial location.

    Reaching a Regulatory Milestone

    The FDA has finished inspecting one site in the TRANQUILITY II Phase 3 study, according to BioXcel. The inspection status was closed and an Establishment Inspection Report was issued by the agency in accordance with 21 C.F.R. 20.64(d)(3). Although minor concerns may have been found, the site was classified as “Voluntary Action Indicated,” which means that regulatory action is not necessary.

    The completion of this inspection, together with the positive results of an independent audit carried out in October 2023, further confirms the accuracy of the trial data, BTAI stressed.

    These results will be included in a prospective supplementary new drug application (sNDA) filing for regulatory evaluation, according to BioXcel. Furthermore, BTAI is proceeding with its primary neuroscience candidate, BXCL501, after receiving FDA comments on the plan for its TRANQUILITY In-Care Phase 3 study.

    Promoting Clinical Development

    BXCL501 is a patented sublingual film formulation of the selective alpha-2 adrenergic receptor agonist dexmedetomidine that has received FDA approval. It is sold under the brand name IGALMI. The experimental formulation is now being studied for the treatment of acute agitation associated with schizophrenia, bipolar disorder, and Alzheimer’s dementia in home-based settings, despite having previously been licensed for certain uses.

    The TRANQUILITY In-Care Trial

    The 12-week, double-blind, placebo-controlled TRANQUILITY In-Care study aims to assess the safety and efficacy of a 60 mcg dose of BXCL501 for agitation associated with Alzheimer’s disease in a care facility setting. BioXcel Therapeutics expects more regulatory contacts as its clinical projects advance, which might affect how its drug development activities develop in the future.

  • Following The Validation Of Trial Results, BioXcel (BTAI) Stock Is Rising

    Following The Validation Of Trial Results, BioXcel (BTAI) Stock Is Rising

    BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares have exhibited a notable surge of 23.08%, reaching $2.88 in the present trading session, as per the most recent data.

    The BioXcel stock was trading in a range spanned from $2.83 to $3.35 during today’s market activity, with a substantial trading volume of over 50 million shares.

    The catalyst for this morning’s ascent in BTAI stock can be attributed to a positive evaluation by an external party concerning the results of its clinical trial.

    Today, BioXcel (BTAI) unveiled encouraging outcomes stemming from an impartial third-party assessment of data from a specific site within its TRANQUILITY II Phase 3 trial.

    This audit, conducted by a well-respected regulatory and quality consulting firm, involved a thorough scrutiny of records pertaining to more than 50% of the trial’s participants at that specific site.

    The primary objectives of the audit encompassed the detection of any potential irregularities, misconduct, or fraudulent activities and an assessment of the integrity and reliability of the data pertaining to eligibility, safety, and efficacy.

    The sample size employed in this assessment ensures a 95% confidence level in the representativeness of the data reviewed.

    Following a comprehensive examination, the team of auditors did not uncover any elements that could compromise the reliability or integrity of the data, nor did they unearth any indications of further misconduct or fraud.

    Based on these findings, BioXcel has the belief that the positive and statistically significant data from the TRANQUILITY II trial, as announced in June 2023, could potentially serve as a basis for a supplemental new drug application (sNDA) for BXCL501, aimed at the acute treatment of agitation associated with dementia in probable Alzheimer’s disease.

    BioXcel is of the opinion that the results of this audit, conducted by a respected and independent entity, affirm the trustworthiness of the data originating from the specific site under scrutiny.

    Furthermore, these results enrich the body of clinical evidence that the company intends to incorporate into its sNDA submission.

    Notably, BTAI has recently conducted a Type B/Breakthrough meeting with the FDA to discuss the development plans for BXCL501 concerning the acute treatment of agitation in the context of dementia related to probable Alzheimer’s disease.

    BioXcel anticipates the receipt of the FDA meeting minutes in the first half of November and intends to provide an update on the subsequent phases of the TRANQUILITY program and the potential sNDA in its forthcoming third-quarter financial report.

  • Here is why BioXcel Therapeutics Inc. (BTAI) underperformed on Tuesday?

    Here is why BioXcel Therapeutics Inc. (BTAI) underperformed on Tuesday?

    BioXcel Therapeutics Inc. (BTAI) stock started the Tuesday, June 22, 2021, trading by losing 3.63% in the morning session and closed at $36.85 per share. The decline continued in the after-market session and BTAI shares further plunged 8.06% and closed the day at $33.88 per share. BTAI shares have fallen 35.32% over the last 12 months, and they have moved down 1.26% in the past week. Over the past three months, the stock has lost 13.48%, while over the past six months, it has declined 28.11%.

    Let’s have a brief look at its recent news and developments.

    Proposed Public Offering of Common Stock

    On June 22, 2021, BioXcel Therapeutics, Inc commenced an underwritten public offering of $100.0 million of shares of its common stock. BioXcel LLC expects to grant the underwriters a 30-day option to purchase up to $15.0 million of additional shares of common stock at the public offering price, less underwriting discounts, and commissions.

    The net proceeds from the offer will be used for funding of clinical trials, commercialization preparation, and general corporate purposes.

    Hosting of  Virtual Commercial Day

    BioXcel Therapeutics will be hosting a virtual Commercial Day on Friday, June 25, 2021, from 12:00 PM ET – 1:30 PM ET.

    The event is organized to provide an update on the Company’s launch readiness plans and market insights for BXCL501. The corporate leadership of the company will be joined by members of the Company’s commercial leadership team, as well as an industry expert, Dr Leslie S. Zun, Professor of Emergency Medicine at Chicago Medical School.

    Participation in recent three upcoming healthcare investor conferences

    BioXcel Therapeutics recently participated in the following healthcare investor conference. The company was presented by Dr Vimal Mehta, Founder and Chief Executive Officer of BioXcel.

    • The company took part in a fireside chat at BofA Securities Napa Biopharma Conference which held on Monday, June 14, 2021.
    • BTAI participated in Goldman Sachs 42nd Annual Global Healthcare Conference which held on Wednesday, June 9, 2021.
    • The company also presented itself in a fireside chat at Jefferies Virtual Healthcare Conference which held on Wednesday, June 2, 2021.

    FDA accepted NDA filing of BXCL501

    On May 19, 2021, BioXcel Therapeutics, Inc said that the U.S. Food and Drug Administration has accepted the filing of a New Drug Application for BXCL501.

    BXCL501 is the Company’s proprietary, investigational, orally dissolving thin film formulation of dexmedetomidine, for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II.

    The FDA has a target action date of January 5, 2022. At this time, the FDA is not planning to hold an advisory committee meeting to discuss the application.

    Conclusion

    The commencing of a public offering of BTAI common stock could be the reason behind its poor performance on Tuesday. We are unsure how BTAI will perform in the remaining days of the week.

  • BioXcel Therapeutics (BTAI) is a hot investment option; Here is what you should know

    BioXcel Therapeutics (BTAI) is a hot investment option; Here is what you should know

    BioXcel is going big—with notable developments—that could push the stock higher than its 52-week high of $71.50, in the coming months.

    BioXcel Therapeutics (BTAI) is making way into a newly evolving industry in the health sciences—biotech. BTAI had a superb last year with notable developments. The popularity of the company is due to its use of artificial intelligence in drug discovery.

    As we write this on Feb. 1, BTAI shares were soaring by 8.96% trading around $50.47.In the past year, when the rest of the stock market was dropping—in March—BioXcel entered the bullish momentum. Initially, the business was paused due to the pandemic restrictions, however, the biotech company kept on performing well.

    What’s Next?

    BioXcelTherapeutics (BTAI) grew its revenue to over20% in the fiscal year 2020. So, the sales were decent enough to push the revenues. For this year, the company projects to maintain organic growth of 15%-20%, with additional acquisitions possibly pushing the overall growth even further.

    BioXcel stands out for its development in AI-based solutions and drug discovery. The biotech firm is incorporating the power of next-generation technology. Through this BioXcel would have a swifter growth and transformation would be phenomenal due to smart tech. This opens up a lot of opportunities for BioXcel to thrive in different segments and diversify its portfolio.

    At the moment, the most significant project of BioXcel is its proprietary, orally dissolving thin film formulation of dexmedetomidine, BXCL501. This topline drug is being developed for the acute treatment of agitation in dementia patients, including those with Alzheimer’s disease.

    Recently, the company announced the topline results from the Phase 1b/2 TRANQUILITY trial of BXCL501. The results from the trials were statistically significant and clinically meaningful. Moreover, BXCL501 showed fast and durable reductions in agitation that was obtained with the 60 mg dose.

    The CEO of BioXcel stated the current analysis shows that BXCL501 has a massive potential to treat the full spectrum of agitation in patients with dementia. The company plans to take the drug trials into a late-stage study later this year, following that dialogue with the FDA.

    It is estimated that around 4 million people in the US are suffering from agitation associated with dementia affects. If BXCL501 achieves all the end-points of the study following the approval from the FDA, it would change things for the patients. Also, this would ultimately bring tons of revenue for the company.

    Conclusion

    BioXcelTherapeutics (BTAI) is still growing with astonishing potential alongside—AI tech is a massive gateway to success. The biotech industry has a wide range and various opportunities to embrace its place in the health market. For investors; with continued growth expected this year, BTAI is a stock to go with.